Sartelli, Massimo
Tascini, Carlo
Coccolini, Federico
Dellai, Fabiana
Ansaloni, Luca
Antonelli, Massimo
Bartoletti, Michele
Bassetti, Matteo
Boncagni, Federico
Carlini, Massimo
Cattelan, Anna Maria
Cavaliere, Arturo
Ceresoli, Marco
Cipriano, Alessandro
Cortegiani, Andrea
Cortese, Francesco
Cristini, Francesco
Cucinotta, Eugenio
Dalfino, Lidia
De Pascale, Gennaro
De Rosa, Francesco Giuseppe
Falcone, Marco
Forfori, Francesco
Fugazzola, Paola
Gatti, Milo
Gentile, Ivan
Ghiadoni, Lorenzo
Giannella, Maddalena
Giarratano, Antonino
Giordano, Alessio
Girardis, Massimo
Mastroianni, Claudio
Monti, Gianpaola
Montori, Giulia
Palmieri, Miriam
Pani, Marcello
Paolillo, Ciro
Parini, Dario
Parruti, Giustino
Pasero, Daniela
Pea, Federico
Peghin, Maddalena
Petrosillo, Nicola
Podda, Mauro
Rizzo, Caterina
Rossolini, Gian Maria
Russo, Alessandro
Scoccia, Loredana
Sganga, Gabriele
Signorini, Liana
Stefani, Stefania
Tumbarello, Mario
Tumietto, Fabio
Valentino, Massimo
Venditti, Mario
Viaggi, Bruno
Vivaldi, Francesca
Zaghi, Claudia
Labricciosa, Francesco M.
Abu-Zidan, Fikri
Catena, Fausto
Viale, Pierluigi
Article History
Received: 26 March 2024
Accepted: 1 June 2024
First Online: 8 June 2024
Declarations
:
: Not applicable.
: Not applicable.
: M.B. received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from Angelini, Biomerieux, Cidara, Gilead, Menarini, MSD, Pfizer, and Shionogi. M.B. participated on data safety monitoring board or advisory board of Angelini, Biomerieux, Cidara, Gilead, Menarini, MSD, Pfizer, and Shionogi. A.C. received fees for lectures or advisory board membership by Gilead, MSD, Mundipharma, Pfizer, Shionogi. F.P. participated in the speaker’s bureau for Angelini, Gilead, Menarini, InfectoPharm, Merck Sharp & Dohme, Pfizer, Shionogi and on the advisory board for Advanz Pharma, Gilead, Merck Sharp & Dohme, Pfizer and Viatris. All the other authors declare that they have no competing interests.